SOURCE: Equity News Circuit

Equity News Circuit

March 25, 2013 08:45 ET

Free Research Reports on CBLI, DRYS, HALO and QCOR Issued by the Bedford Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT

NEW YORK, NY--(Marketwire - Mar 25, 2013) - The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Cleveland BioLabs, Inc. (NASDAQ: CBLI) shares spiked 9.74 percent on nearly eight times the average daily volume traded Friday to close at $2.14 a share. The company swing to a net income of $3.1 million for the fourth quarter of 2012, compared to a net loss of $7.2 million in the year ago quarter.

Find out more about Cleveland BioLabs including full access to the free equity report at: www.BedfordReport.com/CBLI

DryShips Inc. (NASDAQ: DRYS) shares have gained over 30 percent year-to-date. The Baltic Dry Index, which measures the costs to ship dry-bulk commodities such as grain, coal and iron ore, surged to 875 points earlier this month, the highest rating of the year.

Find out more about DryShips including full access to the free equity report at: www.BedfordReport.com/DRYS

Halozyme Therapeutics, Inc. (NASDAQ: HALO) shares soared 30.93 percent on over six times the average daily volume Friday to close at $6.90 a share. The company announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has granted a Positive Opinion to Baxter for HyQvia as a treatment for primary and secondary immunodeficiencies.

Find out more about Halozyme Therapeutics including full access to the free equity report at: www.BedfordReport.com/HALO

Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) shares declined 7.48 percent on volume of 3.68 million shares traded Friday to close at $32.54 a share. The company announced it shipped 6,330 vials of Acthar during the fourth quarter 2012, an increase of 88 percent when compared to the year ago quarter.

Find out more about Questcor Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/QCOR

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.

A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information